Quantcast
Last updated on April 19, 2014 at 13:20 EDT

Gammagard Approved for Multifocal Motor Neuropathy: Severe Adverse Events

June 26, 2012

Yesterday, Baxter International Inc. announced that, its drug, Gammagard Liquid 10% [Immune Globulin Infusion (Human)] was approved by the U.S. FDA as a treatment for multifocal motor neuropathy or MMN. Gammagard is an intravenous solution that is made from human plasma. It is a sterile solution, which helps the body maintain immunity and fight disease. In February 1994, Baxter announced it was removing Gammagard from the global market because of the possibility that it may have transmitted the hepatitis virus, including hepatitis C. Now, AttorneyOne.com, a recognized authority on law, can provide helpful, proven advice and simple solutions including how to get in contact with legal counsel so anyone can easily and inexpensively deal with cases of Gammagard severe adverse events. http://www.attorneyone.com/gammagard-lawsuits/.

San Diego, CA (PRWEB) June 26, 2012

The media spotlight is often a double-edged sword. No one knows this better than people who suffer from Gammagard´s severe adverse events. And yet, gossip and rumor-mongering aside, the real story here is being overlooked according to Sean Burke of AttorneyOne.

Yesterday, Baxter International Inc. announced that, its drug, Gammagard Liquid 10% [Immune Globulin Infusion (Human)] was approved by the U.S. FDA as a treatment for multifocal motor neuropathy or MMN. Gammagard is an intravenous solution that is made from human plasma. It is a sterile solution, which helps the body maintain immunity and fight disease.

According to the announcement, the approval was based on the results of a randomized, double-blind, placebo controlled, cross-over study conducted to evaluate the efficacy and safety/tolerability of Gammagard Liquid in 44 adult subjects with MMN. The most common adverse reactions (observed in 5% of subjects) during infusion with Gammagard Liquid were headache, chest discomfort, muscle spasms, muscular weakness, nausea, oropharyngeal pain, and pain in extremity. The serious adverse reactions were pulmonary embolism and blurred vision which were judged to be treatment-related.

In February 1994, Baxter announced it was removing Gammagard from the global market because of the possibility that it may have transmitted the hepatitis virus, including hepatitis C.

AttorneyOne.com, a recognized authority on law, can provide helpful advice and simple solutions including how to get in contact with legal counsel so that, in case of severe complications from Gammagard, someone can easily and inexpensively deal with it. As Mr. Burke, director of Media Relations for AttorneyOne.com, added, “What all this information really illustrates is that threat from Gammagard remains. For that reason, our focus should squarely fall on getting the word out and assisting people in finding the right legal assistance.”

In March 2012, the US FDA announced that Baxter Healthcare voluntarily recalled specific lot of Gammagard Liquid 10% 20g as a precautionary measure due to a labeling error (incorrect manufacturing date and expiry date ) noted on the product vial label and unit carton.

AttorneyOne.com has further information on Gammagard lawsuits including how to get in contact with legal counsel.

Headquartered in San Diego, CA Attorney One was founded in 2004 and is not a law firm. They offer a nationwide legal service which helps consumers find the best representation for their legal needs. You can learn more about Attorney One at our website http://www.attorneyone.com. You can also find us on Facebook at http://www.facebook.com/AttorneyOne. Checkout earlier news from us at http://www.prweb.com/releases/2012/6/prweb9635118.htm.

For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2012/6/prweb9638437.htm


Source: prweb